Relmada Therapeutics, Inc. · NASDAQ:RLMD
Relmada Therapeutics — Investor Presentation (September 2014)
25 slides from Relmada Therapeutics's investor presentation, Sep 11, 2014
Slide 1: Relmada Therapeutics: Innovations in Pain Medicine
et RELMADA THERAPEUTICS Innovations in Pain Medicine™ September 2014
Slide 2: Disclaimer and Safe Harbor Statement
—— —— Disclaimer and Safe Harbor Statement Disclaimer @ The contents of this presentation and the information whieh you ace given at the time of these slides and the presentation have not been approved. by an authorized persion wit {ior the purpose of engaging in investment activity may expose an in
Slide 3: Investment Highlights
VEE Investment Highlights ¢ Robust portfolio of four drugs in development that address unmet needs in the largest drug prescription market in the world: the treatment of pain Three products combine proven drug candidates with novel delivery methods to create new drugs with new indications, while the
Slide 4: Value Creation Development
—ylyLL = — — — —SE—EE Value Creation Development © Attracted stellar talent to the company V-_ Bliseo Salinas, MD, President & Chief Scientific Officer Douglas Beck, CPA, Chief Financial Officer Y-Shieesam N, Aghaskar, Ph.D, Dizector Nabil M. Yazgi, MD, Director Closed $8M Series A Preferred Stock p
Slide 5: Core Team
—ylyllll] a —— — — ——— EE Core Team Background Sergio Travers Phas ‘Former CEO of Med, Tne. (Acquiei by Remad) Greeaneiies es er ee oo eens eon eee ce caemeeel (Meh & Isly, ING Barings, Merlin BioMed & Re Capita) and in industry (iil, Je) |¢ MBA, Finance at New York University Lawes of Pharmacy at t
Slide 6: Scientific Advisory Board
Ly ——— — — ————EEE Scientific Advisory Board Nathaniel Katz, MD Chief Executive Analgesic Solutions, LLC 4 Fonner Chair FDA Advisory Committee, Anesthesia, Critical Case, & Addiction # Founder, Pain Mgmt Program & Pain "Tsials Unit, Dana Pasher Cancer Institute Troels Jensen, MD, PhD # Past Presiden
Slide 7: The Market for Pain Drugs
yay — EEE The Market for Pain Drugs Largest prescription drug market in the world — 334 million RXs in US in 2013 @ Affects 1.5 billion+ people worldwide © Most frequent re the United States son for physician vis Affects more Americans than diabetes, heart disease and cancer combined US annual econo
Slide 8: Large Market
yl] — — — LE Large Market 2013 RXs 2013 Sales US Marker Da US Masket Dats m= NARCOTIC lmNON-NARCOTIC Oxycontin Oxycodone 59M Oxycontin Oxycodone 82,535M Vievdin* Hydrocodone/apap 126.5 M. Vicodin® Hydrocodone/apap $1,051 M SERRA ism Ldccsncpach yg SUS i, Lidocincpach sou M Fentanyl” Fentanyl 67M Ken
Slide 9: Classifying Pain
——— —— —=——— Classifying Pain Relmada’s ‘Target Market Chronic Mixed Visceral Nociceptive Neuropathic I 1 I 1 I I =n 1 1 : entral Peripheral : 1 1 1 I 1 0 f J ! : 1 Postherpetic fe Bowsaurgieal {+ Poststroke oe + Internal organs pain + Osteoarthritis || Mutiple sclerosis | | Diabetic neuropathy + Pa
Slide 10: Relmada's Multi-Product Approach
Relmada’s Multi-Product Apptoach Relmada’s products target every level of the pain spectrum Products in Market ica oo si(M9) Kadian@** Avinza® Opanat* Nucynta® OxyContin® Vicodin®* Ultram®* 173 BuTrans® Suboxone® Lytica® Cymbalta® Gabapentin®* $ 264 114 Mild ' Lidoderm®** “Includes geneties; * Peak
Slide 11: Chief Scientific Officer Key Career Drug Approvals
Chief Scientific Officer Key Cateer Drug Approvals An impressive track record developing successful drugs Company Product Tysasrl. élan — Gonat> Ghire FOSRENOL: Tlorthonum carbonate) Fa: fe ‘trana® ¢ mapas Wyeth [_ Sonce: Med Track et Sales Type Worldwide USA USA USA & Europe USA North America World
Slide 12: Robust Product Portfolio
NEE EERE Tt SS Robust Product Portfolio Significant value creation possible in 12-18 months due to accelerated development timelines HM Corrent Stage of Development | Projected Stage of Development in 12-18 months Product Description Indication . Phase Phase2 Phase 3 Extended Release Moderate/Severe
Slide 13: Development Strategy Benefits — 505(b)(2)
Development Strategy Benefits — 505(b)(2) 505(b)(2) Strategy allows Relmada to bring repurposed drugs to market faster and at a fraction of the cost of typical drug development * The 505(b)(2) application: the sponsor can reference to an approved product for preclinical, safety and efficacy data @ A
Slide 14: LevoCap ER - Lead Product
a —>E—E— LevoCap ER - Lead Product @ Pharmacologically differentiated from morphine, oxycodone and all strong opioids Large clinical experience with IR form in chronic pain Multimode! mechanism of action can be basis for successfully launching a once daily product Approved label for IR:“management o
Slide 15: How LevoCap ER Works
EEE —PE>-——— How LevoCap ER Works Levorphanol’s multi-modal mechanism of action provides for a more robust efficacy profile and potentially could be used alone for patients who take multiple drugs Opioid Mechanism Non-Opioid Mechanism Ascending Pathways Descending Pathways Serotonin-Norepinephrine R
Slide 16: LevoCap ER Market Potential Survey Report
LevoCap ER Market Potential Survey Report Product Profile Evaluation Topline Report Aagurteatty May 200, 2033 et ORGinternational The survey evaluated the potential for LevoCap ER in the opioid / pain management space It was conducted with a mix of 150 physicians specializing in pain management Curr
Slide 17: Neuropathic Pain — An Unresolved Disease
yl — EEE Neuropathic Pain — An Unresolved Disease Neuropathic pain represents a large market opportunity ready for a new effective entry @ Neuropathic pain is a result of a malfunctioning of the nervous system and includes post herpetic neuralgia (PHN), painful diabetic neuralgia (PDN), and HIV-rela
Slide 18: d-Methadone — Significant Upside Potential
d-Methadone — Significant Upside Potential Potential blockbuster drug to treat neuropathic pain Features and Benefits # Created by separating the d- from I isomer of 4 methadone # Potential to provide pain relief without the ¢ addiction hazard of methadone # Promising results in a Phase I/Ila study
Slide 19: BuTab ER - Dual Purpose Product
yyy ESE BuTab ER - Dual Purpose Product The first form of buprenorphine in a tablet for use in pain and treating addiction Only tablet form of buprenorphine for use in pain treatment — Other forms Butrans® (patch) & Suboxone® (for opioid addiction only) have combined sales of $1.6 billion+ Two indic
Slide 20: Market Potential of BuTab ER
yl ——— — —E—— EE Market Potential of BuTab ER BuTab ER can compete in the $8.3 billion opioid market for pain and the $1.5 billion market for opioid addiction if approved 1* Indication Precedence in Pain Treatment # Butrans® is a recently formulation of buprenorphine launched patch # Sales growth su
Slide 21: MepiGel — Disruptive Topical Delivery System
MepiGel — Disruptive Topical Delivery System First topical gel dosage form of any local anesthetic for the treatment of neuropathic pain Fe and Ben + Received two FDA orphan drug designations — “the management of postherpetic neuralgia®” — “the treatment of painful HIV-associated neuropathy**” ¢ 7-y
Slide 22: Market Potential of MepiGel
Market Potential of MepiGel MepiGel will compete directly with Lidoderm® patch and its $948 million in sales if approved % Better efficacy . mre — Greater skin penetration a5 — Greater skin retention + Easier to use and more practical — Patch has poor adhesion to hands, feet and hairy skin US. Sales
Slide 23: Near-term Value Drivers
—E——PE>>->———— Near-term Value Drivers Multiple development milestone potential in next 12-18 months as Relmada’s products advance to a new stage of development * LevoCap ER * Uplisting to National Exchange — Transfer manufacture technology — FDA end of Phase I meeting @ Research Coverage — Start Ph
Slide 24: Licensing
Eyl —— ——E— LEE Licensing Licensing activity can be ignificant driver of value creation all figures in $M ‘Market Value Added Dea ™ Company Exchange: Ticker Product Deal Description me at Deal HZ Announcement ‘Xenoa Private ‘XEN402 “TEVA signs licensing deal 376 Private ala afa Pharmaceuticals agree
Slide 25: Investment Highlights
VEE Investment Highlights ¢ Robust portfolio of four drugs in development that address unmet needs in the largest drug prescription market in the world: the treatment of pain Three products combine proven drug candidates with novel delivery methods to create new drugs with new indications, while the
Relmada Therapeutics — Investor Presentation (September 2014) on 6ix